Guidelines for Poster and Flash Presentation / SUBMSSION GUIDELINES

Guidelines for Poster and Flash Presentation

  1. Poster size: Posters must be printed in portrait orientation, no larger than A0 (90cm wide x 140cm high).
  2. E-Poster submission: If your poster can let us post in an electric billboard, please e-mail your poster to us ( ) before the 16 November. The file name of the e-Poster must be named as follows: poster number plus the first author’s name (e.g. PA01-Wang Ching Chiung) and converted into a PDF file (Portable Document Format). The file resolution must be 300 DPI, and the file size should less than 2 MB.
  3. PPT file of the Poster Oral presentation (Flash presentation) submission: At the Conference we expect you to present your poster as a ‘three minute flash’ presentation (two to four slides only). If you would like to join the Flash presentation, please e-mail your PPT file to us ( ) before the 20 November. The file name of the PPT must be named as follows: poster number plus the first author’s name (e.g. PA01-Wang Ching Chiung).
  4. Schedule of Poster Presentation
  • Time for mounting posters: at 16:00-19:00, 24 November.

The conference organizers will mark the poster number on each board. You can be directed to the location where you can mount your poster. We will prepare the removable double sided adhesive on each board.

  • Time for displaying posters: at 08:00- 17:00, 25 November. Then you must take down your poster before 18:00.
  • Time for displaying e-Poster: at 08:00, 25 November to 17:00, 26 November.
  • The flash presentations will take place on Mon 26 November in the afternoon.

Poster Competition include the Flash presentation would be held at the ICOM. Certificate and Premium would be granted for the excellent posters.



Poster submission deadline extended to 9/30
Paper submission deadline 8/31



Abstracts Format

 All abstracts (except for Case Report) must contain the following information: Introduction, Materials & Methods, Results and Conclusion. Abstracts should be no more than 400 words. Tables or figures are not allowed. All abstracts must be submitted and presented in English.

Poster Presentation

 Size of Poster: 90cm(W) x140cm(H), Masthead of Poster: Title of Paper, Author’s Name, Work unit.





Vitisin B stimulates osteoblastogenesis via estrogen receptor


Yu-Ling Huang 1,2, Wen-Fei Chiou 1, 3,4,*


1 National Research Institute of Chinese Medicine, Taipei, Taiwan

2 Department of Cosmetic Science, Chang Gung University of Science and Technology, Taoyuan, Taiwan

3 Department of Biotechnology, Hungkuang University, Taichung, Taiwan

4 Ph.D Program for the Clinical Drug Discovery from Botanical Herbs, Taipei Medical University, Taipei, Taiwan 

Vitisin B is one of the major components existed in Vitis thunbergii, a herbal medicine used in Taiwan for treatment of inflammatory bone diseases. The present study further delineated the action mechanism(s) by which vitisin B stimulates osteoblastogenesis by using MC3T3-E1 cells. Results showed that vitisin B evoked estrogen receptor (ER)-dependent increases in alkaline phosphatase (ALP) activity, bone mineralization, mRNA expression of osteoblast-characteristic genes (collagen type I, bone morphogenetic protein 2, bone sialprotein and osteocalcin) and transcription factors (Runx2 and osterix) in MC3T3-E1 cells. Vitisin B and 17b-estradiol (E2) both induced ER-mediated rapid phosphorylation of Src kinase. Furthermore, the rapid estrogenic phosphorylation, the expression of osteoblast-characteristic genes and final bone mineralization were all blocked in the presence of PP2. After investigation the involvement of MAPKs results demonstrated that vitisin B also evoked a Src-mediated phosphorylation of p38 and ERK through ER-dependent pathway. These findings indicated that vitisin B exerts anabolic effects in bone possibly by activating non-genomic signaling pathway through ER-mediated activation of Src kinase. Its ability to prevent ovariectomy-induced bone loss supports its use as an alternative regimen for management of postmenopausal osteoporosis.


Key words: Vitisin B, Osteoblast, Osteoids, Runx2, Osterix, Estrogen receptor, Src